A5043905278- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer survivorship and care
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Screening and Detection
- Radiomics and Machine Learning in Medical Imaging
- Biosimilars and Bioanalytical Methods
- Drug-Induced Adverse Reactions
- Gastric Cancer Management and Outcomes
- Nausea and vomiting management
- Economic and Financial Impacts of Cancer
- Anesthesia and Pain Management
- Renal cell carcinoma treatment
- Chronic Lymphocytic Leukemia Research
- Circadian rhythm and melatonin
- Inflammatory Biomarkers in Disease Prognosis
- Metastasis and carcinoma case studies
- Palliative Care and End-of-Life Issues
- Neuroendocrine Tumor Research Advances
University of Turin
2012-2021
Ospedale San Luigi Gonzaga
2013-2021
A. O. Ordine Mauriziano di Torino
2017-2021
University of Messina
2021
Royal Marsden NHS Foundation Trust
2016-2019
Royal Marsden Hospital
2017
Associazione Italiana Di Oncologia Medica
2014
Ospedale San Bassiano
2013
The role of surgery for lung metastases (LM) secondary to colorectal cancer (CRC) remains controversial. bulk evidence is derived from single surgical series, hampering any definitive conclusions. aim this study was compare the outcomes CRC patients with LM submitted those who were not.Data 409 as first advanced disease extracted a database 1,411 patients. Patients divided into three groups: G1, comprised 155 pulmonary and extrapulmonary metastases; G2, 104 only no surgery; G3, 50 surgery.No...
Abstract Background Although treatment of localized anal cancer (AC) is well established, very little evidence available to inform the management advanced tumors, and prognosis these patients remains poor. We have analyzed pathways outcomes a single-institution series AC in order provide insight into this rare condition. Materials Methods Inclusion criteria included epidermoid histology, inoperable locally recurrent or metastatic disease, availability full medical records. The primary...
Serum marker evaluation is an easily available prognostic indicator that may help clinicians to discriminate patients with aggressive disease; there are few and small-sized studies exploring the role of baseline carcinoembryonic antigen (CEA) values their variations during first-line therapy, even fewer data for carbohydrate 19-9 (CA 19-9). Our aim was analyze those markers exploit them in daily clinical practice. Data 892 determination before 3 and/or 6 months therapy were extracted from...
BackgroundChemotherapy is the mainstay treatment for advanced biliary cancer (ABC). Best supportive care and clinical trials are currently alternative options. The identification of a prognostic score that can be widely applied to daily practice has potential better inform management ABC patients.MethodsA cohort 123 patients undergoing first-line chemotherapy was used as an exploratory define value laboratory tests routinely performed in practice. Kaplan–Meier analysis investigate...
Insulinoma is a rare form of insulin-secreting pancreatic islet cell neuroendocrine (NE) tumor. The medical treatment the malignant NE disease pancreas deeply changed in last years, thanks to introduction new target molecules, as everolimus. Even if exact mechanism not actually known, one side effects everolimus, hyperglycemia, has been demonstrated be useful contrast typical hypoglycemia insulinoma. We report case patient with metastatic insulinoma treated intermittent obtaining an...
Abstract Background The potential of chemotherapy as salvage treatment after failure neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC) has never been explored. We conducted a single-center, retrospective analysis to address this question. Patients and Methods with newly diagnosed LARC who were inoperable or candidates extensive (i.e., beyond total mesorectal excision [TME]) surgery long-course received included. primary objective was estimate the proportion patients...
Direct oral anticoagulants (DOACs) were developed to avoid the limitations of vitamin K antagonists (VKAs). DOACs are associated with a greater incidence gastrointestinal bleeding and smaller number intracranial haemorrhages than VKAs. Therefore, it is important deepen our knowledge their safety profiles. The aim this study was thus analyse adverse drug reaction (ADR) reports on VKAs using Sicilian Spontaneous Reporting System (SRS) database.All ADR as suspected drugs that entered into SRS...
Medical records are a relevant source for real-world evidence. We introduced patient-reported outcomes (PROs) in clinical practice, demonstrating significant quality-of-life improvement, compared to usual visit. In this secondary analysis, we describe the agreement between patients' and physicians' reports of 5 symptoms. Our hypothesis was that adoption PROs questionnaire could significantly improve agreement.Eligible patients were receiving active anti-cancer treatment. Patients control...
Background: Generic anticancer drugs represent an opportunity in terms of cost savings but there are some concerns about their tolerability. The safety profiles generic versus branded oxaliplatin formulations have never been studied detail. Patients and Methods: We tested vitro concentrations, stability efficacy formulations, then we retrospectively collected data hypersensitivity reactions (HSR) 427 colorectal cancer patients treated with oxaliplatin-based regimens. Results: No significant...
11508 Background: Almost half of RAS and BRAFwt mCRC patients do not respond to anti-EGFRs. Different molecular alterations suggested as predictors resistance have been validated. Methods: We conducted a case-control study prospectively demonstrate the negative predictive impact HER-2 amplification or mutations (mut), MET amplification, NTRK/ROS1/ALK/RET rearrangements, mut activating MAPKs PI3K/Akt axis. Patients with clearly resistant (cases) sensitive (controls) anti-EGFRs were selected....
The management of advanced colorectal cancer patients differs among centers. International guidelines recommend offering all the recognized active regimens in order to obtain survival advantage, but little information is given about sequence and combination which such should be administered.We report case a man with multiple liver metastasis from followed for more than 78 months at our Institution. Repeated response same oxaliplatin, 5-fluorouracil folinic acid chemotherapy schedule was...
Seasonal variation of baseline diagnosis (or clinical suspect) stage I-III colorectal cancer patients has been repeatedly reported as an independent variable influencing overall survival. However, data are conflicting and no information is available about such a rhythm in advanced patients. To test whether circannual efficacy outcomes can be detected this setting, we collected response rate (RR), progression-free survival (PFS), (OS) to first-line chemotherapy 1610 newly diagnosed metastatic...
Background The management of advanced colorectal cancer patients differs among centers. International guidelines recommend offering all the recognized active regimens in order to obtain survival advantage, but little information is given about sequence and combination which such should be administered. Case report We case a man with multiple liver metastasis from followed for more than 78 months at our Institution. Repeated response same oxaliplatin, 5-fluorouracil folinic acid chemotherapy...